We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

15 hedge funds and large institutions have $1.12M invested in InVivo Therapeutics Holdings Corp in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

5% more capital invested

Capital invested by funds: $1.06M → $1.12M (+$58K)

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$242K
2
CH
CVI Holdings
Delaware
+$218K
3
BCM
Bridgeway Capital Management
Texas
+$50.8K
4
Northern Trust
Northern Trust
Illinois
+$29K
5
JP Morgan Chase
JP Morgan Chase
New York
+$4.35K

Top Sellers

Rank Fund Capital Flow
1
WS
Wedbush Securities
California
-$78K
2
Two Sigma Investments
Two Sigma Investments
New York
-$23K
3
UBS Group
UBS Group
Switzerland
-$17.4K
4
ICM
IMS Capital Management
Oregon
-$4.35K
5
Morgan Stanley
Morgan Stanley
New York
-$1.45K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$547K +$242K +167 +53%
CH
2
CVI Holdings
Delaware
$279K +$218K +150 +156%
Vanguard Group
3
Vanguard Group
Pennsylvania
$130K – – –
BCM
4
Bridgeway Capital Management
Texas
$39K +$50.8K +35 New
ICM
5
IMS Capital Management
Oregon
$35K -$4.35K -3 -7%
BlackRock
6
BlackRock
New York
$30K – – –
Northern Trust
7
Northern Trust
Illinois
$23K +$29K +20 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$15K – – –
Morgan Stanley
9
Morgan Stanley
New York
$8K -$1.45K -1 -13%
PWM
10
Paulson Wealth Management
Illinois
$4K – – –
MAM
11
Meeder Asset Management
Ohio
$4K +$1.45K +1 +33%
JP Morgan Chase
12
JP Morgan Chase
New York
$4K +$4.35K +3 New
NCM
13
Next Capital Management
New York
$2K +$2.9K +2 New
AG
14
Advisor Group
Arizona
$1K – – –
VFA
15
Valeo Financial Advisors
Indiana
$1K – – –
BNP Paribas Financial Markets
16
BNP Paribas Financial Markets
France
$2 – – –
WS
17
Wedbush Securities
California
– -$78K -52 Closed
Two Sigma Investments
18
Two Sigma Investments
New York
– -$23K -15 Closed
UBS Group
19
UBS Group
Switzerland
– -$17.4K -12 Closed
FIA
20
FNY Investment Advisers
New York
– -$1K -1 Closed

NVIV Hedge Fund Activity: Q4 2018 in Review

15 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2018, worth a combined $1.12M — up 5.5% from $1.06M a quarter earlier.

Fund positioning in NVIV was balanced in Q4 2018: 4 funds opened new positions, 4 closed out, 3 added to existing stakes and 2 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $242K. The largest seller was Wedbush Securities, exiting entirely with an estimated $78K sold.

  • 15 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $1.12M of InVivo Therapeutics Holdings Corp stock for Q4 2018, up 5.5% quarter-over-quarter.
  • 4 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2018 and 4 closed out, a net change of 0 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q4 2018 was Renaissance Technologies, an estimated $242K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q4 2018 was Wedbush Securities, an estimated $78K sold.

Based on aggregated 13F filings for Q4 2018.